Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Multiple Sclerosis, Relapsing-Remitting

Known as: Remitting Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis, Remitting-Relapsing 
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The NFE2L2 gene encodes the transcription factor Nrf2 best known for regulating the expression of antioxidant and detoxification… Expand
  • table 1
  • table 2
Review
2018
Review
2018
The immunomodulatory drug fingolimod (FTY720, GilenyaR) was approved for oral treatment of relapsing-remitting multiple sclerosis… Expand
  • table 1
  • table 2
  • table 3
  • figure 2
Highly Cited
2012
Highly Cited
2012
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
BACKGROUND Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 3
Highly Cited
2010
Highly Cited
2010
BACKGROUND Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes… Expand
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 3
Highly Cited
2008
Highly Cited
2008
BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may… Expand
  • figure 1
  • table 1
  • table 1
  • table 2
  • table 3
Highly Cited
2003
Highly Cited
2003
BACKGROUND In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Highly Cited
2002
Highly Cited
2002
BACKGROUND Treatment options for patients with secondary progressive multiple sclerosis are few. Encouraging results in open… Expand
Highly Cited
2001
Highly Cited
2001
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on… Expand
Highly Cited
2000
Highly Cited
2000
BACKGROUND The influence of the patterns of onset of multiple sclerosis and relapses of the disease on the time course of… Expand